Hubbry Logo
Oxytocin (medication)Oxytocin (medication)Main
Open search
Oxytocin (medication)
Community hub
Oxytocin (medication)
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Oxytocin (medication)
Oxytocin (medication)
Oxytocin (medication)
View on Wikipedia
from Wikipedia

Oxytocin (medication)
Clinical data
Pronunciation/ˌɒksɪˈtoʊsɪn/
Trade namesPitocin, Syntocinon, Viatocinon, others
AHFS/Drugs.comMonograph
MedlinePlusa682685
License data
Pregnancy
category
  • AU: A
Routes of
administration		Intranasal, intravenous, intramuscular
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismLiver and elsewhere (via oxytocinases)
Elimination half-life1–6 min (IV)
~2 h (intranasal)[4][5]
ExcretionBile duct and kidney
Identifiers
  • 1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC43H66N12O12S2
Molar mass1007.19 g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
  • InChI=1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1 checkY
  • Key:XNOPRXBHLZRZKH-DSZYJQQASA-N checkY
  (verify)

Synthetic oxytocin, sold under the brand name Pitocin among others, is a medication made from the peptide oxytocin.[6][7] As a medication, it is used to cause contraction of the uterus to start labor, increase the speed of labor, and to stop bleeding following delivery.[6] For this purpose, it is given by injection either into a muscle or into a vein.[6]

Oxytocin is also available in intranasal spray form for psychiatric, endocrine and weight management use as a supplement. Intranasal oxytocin works on a different pathway than injected oxytocin, primarily along the olfactory nerve crossing the blood–brain barrier to the olfactory lobe in the brain, where dense magnocellular oxytocin neurons receive the nerve impulse quickly.

The natural occurrence of oxytocin was discovered in 1906.[8][9] It is on the World Health Organization's List of Essential Medicines.[10]

Medical uses

[edit]

An intravenous infusion of oxytocin is used to induce labor and to support labor in case of slow childbirth if the oxytocin challenge test fails. The physiology of labor stimulated by oxytocin administration is similar to the physiology of spontaneous labor.[11] It is associated with less tachysystole (more than five contractions in 10 minutes, averaged over a 30-minute period, which can but does not always cause fetal distress) than other induction methods and allows achievement of delivery with amniotomy to proceed faster.[12][13] Whether a high dose is better than a standard dose for labor induction is unclear. It has largely replaced ergometrine as the principal agent to increase uterine tone in acute postpartum hemorrhage. Oxytocin is also used in veterinary medicine to facilitate birth and to stimulate milk release.

The tocolytic agent atosiban (Tractocile) acts as an antagonist of oxytocin receptors. It is registered in many countries for use in suppressing premature labor between 24 and 33 weeks of gestation. It has fewer side effects than drugs previously used for this purpose (such as ritodrine, salbutamol and terbutaline).[14]

Oxytocin has not been found to be useful for improving breastfeeding success.[15]

Contraindications

[edit]

Oxytocin injection (synthetic) is contraindicated in any of these conditions:[16]

Side effects

[edit]

Oxytocin is relatively safe when used at recommended doses, and side effects are uncommon.[17] These maternal events have been reported:[17]

Many of these side effects are unable to be differentiated from the risks of normal labor versus oxytocin administration itself.[18][19]

Oxytocin during labour is associated with a significantly higher risk of severe postpartum hemorrhage.[20]

Excessive dosage or long-term administration (over a period of 24 hours or longer) has been known to result in tetanic uterine contractions, uterine rupture, sometimes fatal. Water intoxication may be exhibited in administration through symptoms such as seizures, comas, neonatal jaundice, and potential fatality.[21] Managed fluid intake and consistent monitoring of sodium levels has been researched as crucial in the safe administration of oxytocin.[22]

The use of oxytocin during childbirth has been linked to an increased need for other medical interventions, most primarily, through the administration of an epidural anaesthetic.[23] This has been documented as creating a 'cascade effect', potentially causing detrimental impacts to the birthing process.[24][25] Oxytocin administration also, conversely, decreases the rate of cesarean sections.[26] Use of oxytocin has been found to significantly shorten labor duration.[26] Early oxytocin augmentation has also been found to increase the probability of spontaneous vaginal delivery and reduce the risk of chorioamnionitis or intrauterine infection.[27][28]

Since a landmark investigation was published in JAMA Pediatrics by researchers in 2013,[29] the potential link between oxytocin use during childbirth and increased risks of Autism Spectrum Disorder (ASD) in children's development has been a topic of debate.[30] There is no robust evidence in support of oxytocin causing ASD or other neurodevelopmental disorders.[31]

Oxytocin was added to the Institute for Safe Medication Practices's list of High Alert Medications in Acute Care Settings in 2012.[32] The list includes medications that have a high risk for harm if administered incorrectly.[32]

During pregnancy, increased uterine motility has led to decreased heart rate, cardiac arrhythmia, seizures, brain damage, and death in the fetus or neonate.[17] Increased uterine motility is a hallmark of both spontaneous labor and induced labor, therefore the risks associated with uterine motility are not specific to this medication.[33]

Use is linked to an increased risk of postpartum depression in the mother.[34]

Certain learning and memory functions are impaired by centrally administered oxytocin.[35] Also, systemic oxytocin administration can impair memory retrieval in certain aversive memory tasks.[36] However, oxytocin does seem to facilitate learning and memory specifically for social information. Healthy males administered intranasal oxytocin show improved memory for human faces, in particular happy faces.[37][38]

Pharmacodynamics

[edit]

In addition to its oxytocin receptor agonism, oxytocin has been found to act as a positive allosteric modulator (PAM) of the μ- and κ-opioid receptors and this may be involved in its analgesic effects.[39][40][41][42][43][44]

Pharmacokinetics

[edit]

Routes of administration

[edit]
A bag of oxytocin for intravenous infusion

One IU of oxytocin is the equivalent of about 1.68 μg or mcg of pure peptide.[45]

  • Injection: Clinical doses of oxytocin are given by injection either into a muscle or into a vein to cause contraction of the uterus.[6] Very small amounts (< 1%) do appear to enter the central nervous system in humans when peripherally administered.[46][better source needed] The compound has a half-life of typically about 3 minutes in the blood when given intravenously. Intravenous administration requires 40 minutes to reach a steady-state concentration and achieve maximum uterine contraction response.[47]
  • Buccal: Oxytocin was delivered in buccal tablets, but this is not common practice any more.[48]
  • Under the tongue: Oxytocin is poorly absorbed sublingually.[49]
  • Nasal administration: Oxytocin is effectively distributed to the brain when administered intranasally via a nasal spray, after which it reliably crosses the blood–brain barrier and exhibits psychoactive effects in humans.[50][51] No serious adverse effects with short-term application of oxytocin with 18~40 IU (36–80 mcg) have been recorded.[52] Intranasal oxytocin has a central duration of at least 2.25 hours and as long as 4 hours.[4][5]
  • Oral: While it was originally assumed that Oxytocin administered orally would be destroyed in the gastrointestinal tract, studies have shown that Oxytocin is transported by the immunoglobulin RAGE (receptor for advanced glycation end products) across the intestinal epithelium and into the blood. Orally-administered Oxytocin has been shown to increase putamen responses to facial emotions in humans.[53] Oxytocin administered orally produces different effects on human behaviour and brain function than when given intranasally, possibly due to variations in the molecular transport and binding mechanisms.

Chemistry

[edit]

Peptide analogues of oxytocin with similar actions, for example carbetocin (Duratocin) and demoxytocin (Sandopart), have been developed and marketed for medical use.[54] In addition, small-molecule oxytocin receptor agonists, like TC OT 39, WAY-267464, and LIT-001 have been developed and studied.[54] However, lack of selectivity over vasopressin receptors has so far limited the potential usefulness of small-molecule oxytocin receptor agonists.[54]

History

[edit]

Oxytocin's uterine-contracting properties were discovered by British pharmacologist Henry Hallett Dale in 1906.[9] Oxytocin's milk ejection property was described by Ott and Scott in 1910[55] and by Schafer and Mackenzie in 1911.[56]

Oxytocin was the first polypeptide hormone to be sequenced[57] or synthesized.[58][59] Du Vigneaud was awarded the Nobel Prize in 1955 for his work.[60]

Etymology

[edit]

The word oxytocin was coined from the term oxytocic. Greek ὀξύς, oxys, and τόκος, tokos, meaning "quick birth".

Society and culture

[edit]

Counterfeits

[edit]

In African and Asian countries, some oxytocin products were found to be counterfeit medications.[61][62]

Other uses

[edit]

The trust-inducing property of oxytocin might help those with social anxiety and depression,[63] anxiety, fear, and social dysfunctions, such as generalized anxiety disorder, post-traumatic stress disorder, and social anxiety disorder, as well as autism and schizophrenia, among others.[64][65] However, a 2013 meta-analysis only autism spectrum disorder showed a significant combined effect size.[66] A 2022 study found an indication of an effect among autistic children aged 3–5, but not among autistic children aged 5-12.[67]

People using oxytocin show improved recognition for positive social cues over threatening social cues[68][69] and improved recognition of fear.[70]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Oxytocin (medication)

View on Grokipedia
from Grokipedia
Oxytocin is a synthetic form of the naturally occurring oxytocin, administered as an injectable medication primarily to initiate or augment during labor and to control postpartum hemorrhage by promoting uterine tone. It is classified as an oxytocic agent and is essential in obstetric care, particularly for conditions such as , premature , or excessive bleeding after delivery. The medication is not intended for elective induction of labor without a medical indication, as overuse can lead to complications like . Oxytocin exerts its effects by binding to G-protein-coupled oxytocin receptors on uterine cells, triggering an increase in intracellular calcium that results in rhythmic contractions of the . It is typically administered intravenously for precise control during , starting at low doses (0.5–2 milliunits per minute) and titrated based on uterine response, or intramuscularly at 10 units postpartum for hemorrhage management. The drug has a short of 1–6 minutes and is rapidly metabolized in the liver and kidneys, requiring continuous monitoring to avoid adverse effects such as or fetal distress. First identified in 1906 and structurally elucidated in 1953, synthetic oxytocin was developed in the mid- by Vincent du Vigneaud, who received the for this achievement, enabling its widespread clinical use. The U.S. (FDA) has approved oxytocin injections, such as Pitocin, for obstetric indications since the 1950s, with ongoing labels emphasizing safe administration in hospital settings. Today, it is included on the World Health Organization's List of Essential Medicines due to its critical role in worldwide.

Clinical Applications

Approved Medical Uses

Oxytocin is primarily approved by the U.S. (FDA) for the induction and augmentation of labor in the antepartum period, particularly in cases of or uterine inertia, where it helps initiate or strengthen to facilitate . This use is supported by randomized controlled trials demonstrating its in managing hypotonic labor, with high-dose regimens shown to shorten labor duration and reduce the need for cesarean sections in select populations. The American College of Obstetricians and Gynecologists (ACOG) recommends oxytocin as a standard agent for when medically indicated, such as in post-term pregnancies or maternal conditions requiring expedited delivery. In the , oxytocin is FDA-approved for the prevention and treatment of postpartum hemorrhage (PPH) by promoting uterine involution and controlling bleeding after delivery. ACOG guidelines designate it as the first-line therapy for PPH due to , with administration typically immediately following delivery. Meta-analyses of randomized controlled trials indicate that prophylactic oxytocin reduces the risk of PPH (defined as blood loss ≥500 mL) by approximately 50% compared to no , and by 41% for severe PPH (≥1000 mL), establishing its critical role in reducing maternal morbidity. Oxytocin has been used, particularly via intranasal administration, to facilitate milk ejection during to support , particularly in cases of insufficient let-down reflex, though this is off-label, less commonly utilized in clinical practice. Internationally, approvals align closely with U.S. indications, but the includes oxytocin on its List specifically for PPH prevention and in low-resource settings, where it addresses high maternal mortality rates from hemorrhage.

Dosage and Administration

Oxytocin is primarily administered intravenously for labor induction and augmentation, with the standard preparation involving the dilution of 10 units (1 mL) in 1,000 mL of a non-hydrating intravenous solution, such as 0.9% sodium chloride, to achieve a concentration of 10 milliunits (mU) per mL. The initial infusion rate is typically 0.5–2 mU/min, titrated upward in increments of 1–2 mU every 15–40 minutes based on uterine response, with a maximum rate of 20–40 mU/min to achieve adequate contractions without hyperstimulation. High-dose protocols, endorsed by the American College of Obstetricians and Gynecologists (ACOG), may start at 4–6 mU/min with larger increments of 4–6 mU every 15–30 minutes for faster labor progression in select cases. Infusion must be delivered via an electronic infusion pump to ensure precise control and prevent dosing errors. For postpartum hemorrhage prevention and management, oxytocin is commonly given as a single 10 international units (IU) intramuscular injection immediately after placental delivery. Alternatively, for intravenous administration in postpartum settings, 10–40 IU may be added to 500–1,000 mL of intravenous fluid and infused continuously at a rate adjusted to maintain uterine tone, often starting at 20–40 mU/min and not exceeding 200 mU/min for therapeutic control of bleeding. Intranasal oxytocin, historically used to facilitate milk ejection in , involves a total dose of 40 IU divided into sprays (e.g., 10 IU per ) administered 2–3 minutes before , though this route is now infrequently recommended due to inconsistent absorption; the commercial intranasal formulation (Syntocinon) was discontinued in 1995, limiting availability to compounded versions. Administration requires continuous monitoring of uterine activity, targeting 200–250 (MVU) over 10 minutes—calculated as the sum of contraction intensities in mmHg—to ensure effective labor without exceeding 400–500 MVU to prevent hyperstimulation or tachysystole (more than five contractions in 10 minutes). Fetal must be surveilled electronically throughout, alongside maternal and , with immediate discontinuation if abnormalities arise. In special populations, such as cesarean sections, prophylactic dosing often includes an initial intravenous bolus of 0.5–3 IU followed by an infusion of approximately 7.72 IU/hour to minimize , per evidence-based protocols. For multiple gestations, standard dosing applies but with heightened vigilance for , as ACOG guidelines emphasize individualized titration and closer monitoring without routine dose reductions.

Safety Profile

Contraindications

Oxytocin administration is absolutely contraindicated in conditions where poses significant risk to the mother or , including complete previa, vasa previa, active , invasive cervical , and or . These scenarios increase the likelihood of severe hemorrhage, , or fetal compromise if labor is induced or augmented. Similarly, oxytocin should not be used in cases of abnormal fetal , such as transverse lie or breech position, or when fetal distress is present and immediate delivery is not feasible, as these can exacerbate hypoxia or malposition-related complications. or hypertonus represents another absolute contraindication, as persistent use heightens the risk of , with reported incidences of 0.5-1% in high-risk scenarios such as trial of labor after cesarean if contraindications are overlooked. Relative contraindications include grand multiparity (five or more previous deliveries), which elevates the risk of and postpartum hemorrhage, necessitating careful risk-benefit assessment before oxytocin use. Prior uterine surgery, such as cesarean section or myomectomy, is also a relative , particularly in trials of labor after cesarean (TOLAC), where oxytocin augmentation increases the risk to around 0.5-1%; guidelines recommend continuous fetal monitoring and prompt discontinuation if hyperstimulation occurs. to oxytocin or its excipients constitutes a relative contraindication, requiring alternative agents or cesarean delivery in affected patients. In maternal conditions like severe , oxytocin is contraindicated or requires extreme caution due to potential induction of , arrhythmias, or myocardial ischemia from fluid overload and hemodynamic shifts. For or severe , oxytocin use is relatively contraindicated if delivery is not imminent, as it may unpredictably alter and exacerbate , with recommendations favoring cesarean section over prolonged infusion.

Adverse Effects

Oxytocin administration, particularly during or augmentation, can lead to , characterized by excessive that may result in fetal distress. Management involves immediate discontinuation of the infusion, maternal repositioning to the left lateral position, and oxygen administration to the mother, with close fetal monitoring to mitigate risks. Prolonged oxytocin infusions, especially when combined with hypotonic fluids, carry a of water intoxication due to its antidiuretic effects, leading to , particularly with excessive fluid administration. Clinical management includes restricting fluid intake to isotonic solutions, monitoring serum sodium levels, and using diuretics like if develops. Cardiovascular effects of oxytocin include (often from rapid intravenous bolus), , and , which are more pronounced post-delivery and can contribute to rare complications such as in overdose scenarios (incidence <1%). These effects are typically transient and managed by slowing the rate, administering vasopressors for if needed, and avoiding bolus dosing where possible, particularly in patients with cardiovascular contraindications. Common non-uterine effects encompass , , and , affecting a notable proportion of recipients during infusion. Rare but serious reactions include allergic responses or seizures from overdose, necessitating prompt infusion cessation and supportive care such as anticonvulsants. Long-term considerations include potential associations between high-dose intrapartum oxytocin and transient postpartum mood alterations, such as increased anxiety or depressive symptoms, as suggested by systematic reviews examining synthetic oxytocin exposure. Screening for mood changes in the early is recommended, with brief interventions like counseling if symptoms emerge.

Pharmacology

Pharmacodynamics

Oxytocin acts as a potent at the (OXTR), a class I (GPCR) predominantly expressed in reproductive tissues such as the and mammary glands, as well as in structures. Upon binding, oxytocin activates the receptor, which couples primarily to Gq/11 proteins, initiating a signaling cascade that mobilizes intracellular calcium essential for its physiological effects. In the uterus, oxytocin binding to myometrial OXTR stimulates phospholipase C-β (PLC-β), which hydrolyzes (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 subsequently binds to receptors on the , triggering the release of calcium from intracellular stores and increasing cytosolic calcium concentrations. This calcium elevation activates , promoting cross-bridge formation between and filaments and resulting in dose-dependent myometrial contractions that vary in frequency and intensity, crucial for labor progression. Beyond uterine effects, oxytocin induces contraction of myoepithelial cells surrounding mammary alveoli through a similar OXTR-mediated PLC-IP3-calcium pathway, facilitating the milk ejection or let-down reflex during lactation. Peripherally administered oxytocin can also influence functions, such as enhancing social bonding and affiliation behaviors, by activating OXTR in brain regions like the and , though the extent of blood-brain barrier penetration remains limited. Genetic variations in the OXTR , particularly the single nucleotide polymorphism rs53576, modulate individual responses to oxytocin. Studies as of 2024 have linked OXTR variants, including rs53576 A-carriers, to higher requirements for oxytocin in maintaining uterine tone postpartum and increased risks of postpartum hemorrhage, potentially due to altered receptor expression or signaling efficiency, highlighting pharmacogenomic influences on therapeutic .

Pharmacokinetics

Oxytocin exhibits route-dependent absorption characteristics, primarily administered via intravenous (IV), intramuscular (IM), or intranasal routes for therapeutic purposes. Intravenous administration provides immediate onset of action due to direct entry into the bloodstream. Intramuscular injection results in a slower onset, with uterine contractions typically commencing within 3 to 5 minutes and persisting for up to 2 to 3 hours. Intranasal delivery, often used in research contexts, demonstrates low systemic bioavailability, estimated at approximately 0.7% to 2%, limiting its peripheral effects compared to parenteral routes. Distribution of oxytocin occurs rapidly throughout the , with a of approximately 0.3 L/kg. The plasma is notably short, ranging from 1 to 6 minutes, attributed to swift enzymatic degradation that necessitates frequent or continuous dosing in clinical settings. of oxytocin is primarily mediated by oxytocinase, also known as leucyl/cystinyl , which hydrolyzes specific bonds in the molecule. This enzyme is abundant in the , liver, kidneys, and plasma, with activity markedly elevated during due to placental production. The resulting metabolites are primarily excreted via the kidneys. Several physiological factors influence oxytocin's . Pregnancy significantly increases the metabolic clearance rate, shortening the and requiring dose adjustments to maintain . In obese patients, higher rates—such as an ED90 of 19.1 IU/h for maintaining uterine tone during cesarean delivery—are often needed compared to non-obese individuals, potentially due to altered distribution or clearance, as evidenced by recent dose-response studies.

Chemical Properties

Molecular Structure

Oxytocin is a cyclic nonapeptide composed of nine amino acids with the sequence Cys¹-Tyr²-Ile³-Gln⁴-Asn⁵-Cys⁶-Pro⁷-Leu⁸-Gly⁹-NH₂, in which the cysteine residues at positions 1 and 6 are linked by a disulfide bridge to form a 20-membered ring. This structure is characterized by the molecular formula \ceC43H66N12O12S2\ce{C43H66N12O12S2} and a molecular weight of 1007.2 Da. The amidated C-terminus contributes to its stability and bioactivity. The disulfide bond is crucial for maintaining the ring conformation, which enables specific interactions with receptors. In comparison to , a structurally related nonapeptide, oxytocin differs at positions 3 ( versus ) and 8 ( versus ), accounting for their distinct physiological roles. Oxytocin exhibits high in water, facilitating its use in injectable formulations. It is stable at physiological but sensitive to and exposure, which can promote degradation and reduce potency. Crystallographic analyses from 2023 have elucidated the structures of oxytocin receptor signaling complexes, confirming the peptide's bioactive conformation and key features for receptor binding.

Synthesis and Formulation

Oxytocin for pharmaceutical use is produced entirely through synthetic methods to ensure consistency and avoid contamination risks associated with extraction from animal sources. While recombinant methods are utilized, the majority of pharmaceutical oxytocin is produced via chemical synthesis to ensure purity and scalability. The first total chemical synthesis of oxytocin was accomplished in 1953 using stepwise solution-phase peptide assembly, enabling the production of the nonapeptide in pure form. Subsequent advancements in solid-phase peptide synthesis (SPPS), pioneered by Robert Bruce Merrifield in 1963, revolutionized its manufacture by anchoring the growing peptide chain to an insoluble resin support, facilitating automated assembly and purification of the cyclic structure. This Merrifield method remains a cornerstone for laboratory-scale and some commercial synthesis due to its efficiency in yielding high-purity oxytocin. In modern industrial production, technology in is used in some productions, offering scalable yields. The oxytocin gene is typically expressed as a precursor, which is cleaved and cyclized post-purification to generate the active hormone, achieving expression levels sufficient for therapeutic quantities. This biotechnological approach minimizes steps while maintaining structural fidelity to the native . Pharmaceutical formulations of oxytocin are designed for precise dosing and stability, primarily as sterile injectable solutions at 10 IU/mL concentration in 1 mL single-dose vials for intravenous infusion or . These aqueous solutions incorporate excipients such as (0.5% w/v) as a to prevent microbial growth and acetic acid for adjustment, enhancing shelf-life under refrigerated storage. Nasal spray formulations, often at 40 IU/mL in multi-dose bottles, provide an alternative non-invasive delivery option, stabilized similarly with preservatives to mitigate oxidation. Quality control for oxytocin medications adheres to United States Pharmacopeia (USP) monograph standards, requiring oxytocic activity between 90% and 110% of the labeled amount, confirmed via or HPLC. Sterility is verified through or direct tests, ensuring absence of viable microorganisms, while purity exceeds 95% with limits on degradation products like deamidated or oxidized impurities not surpassing 12.5%. Challenges in include monitoring thermal and photodegradation, which can form inactive byproducts, necessitating protected and cold-chain . As of 2025, advancements in formulation include , where chains are conjugated to the of oxytocin to enhance its storage stability, improving resistance to heat and degradation for better in resource-limited settings.

Historical Development

Discovery and Isolation

The discovery of oxytocin's physiological effects began in 1906 when British pharmacologist Sir Henry Dale demonstrated that extracts from the posterior lobe of the induced strong contractions in the uterine muscle of cats, highlighting its potential role in . This observation laid the groundwork for recognizing the pituitary as a source of uterine-stimulating substances, though the active component remained unidentified. In the , studies on extracts advanced with the commercialization of Pituitrin, a bovine preparation introduced by & Company in 1909, which was linked to both pressor and oxytocic activities in early physiological assays. These extracts, derived from animal , were tested in animal models to explore their effects on , including the , confirming the presence of a potent contractile agent. Key milestones in the 1930s included animal experiments that further validated the labor induction potential of extracts, such as studies in rabbits and cats showing intravenous administration could trigger coordinated mimicking parturition. The isolation of oxytocin occurred in the early 1950s under American biochemist Vincent du Vigneaud, who purified the hormone from pig extracts in 1953 and elucidated its structure as a cyclic nonapeptide—the first to have its sequence fully determined. For this achievement, along with the first of oxytocin, du Vigneaud was awarded the in 1955.

Clinical Introduction and Etymology

Oxytocin, a peptide hormone, transitioned from laboratory discovery to clinical application in the mid-20th century, primarily for facilitating labor and preventing postpartum hemorrhage. Initial clinical trials in the 1940s explored its use for labor induction, with Edward W. Page proposing intravenous infusion of pituitary extracts containing oxytocin in 1943 to achieve controlled uterine contractions. By 1949, Geoffrey W. Theobald reported promising results from intravenous drip administration in a series of cases, demonstrating safer and more predictable labor augmentation compared to earlier intramuscular methods. These trials laid the groundwork for broader adoption, culminating in the structure elucidation of oxytocin in 1953 and its synthesis in 1954 by Vincent du Vigneaud, who enabled production of the synthetic form marketed as Pitocin. The U.S. Food and Drug Administration approved synthetic oxytocin for clinical use in labor induction and postpartum hemorrhage control in the 1950s, marking a pivotal shift from animal-derived extracts to standardized pharmaceutical preparations. Key milestones in oxytocin's clinical evolution followed in subsequent decades. In the , standardization of intravenous protocols advanced, replacing intermittent intramuscular injections with continuous gravity-assisted infusions, which allowed for precise dosing and reduced risks of ; this era saw oxytocin become the dominant method for worldwide. The endorsed oxytocin in the 1980s as part of the Safe Motherhood Initiative launched in , promoting its use in developing countries to address maternal mortality from postpartum hemorrhage, though access challenges persisted due to cold-chain requirements. More recently, 2022 updates from initiatives like Merck for Mothers emphasized equitable distribution and quality assurance of oxytocin to bridge gaps in maternal care, particularly in low-resource settings, aligning with global goals for . The term "oxytocin" originates from the Greek words oxys (swift or quick) and tokos (birth), coined by in 1906 to reflect the substance's rapid induction of observed in . This captured its primary therapeutic role in expediting labor. Regulatory evolution paralleled technological advances: early reliance on extracts gave way to synthetic oxytocin by the mid-1950s, improving purity and consistency. Although specific patents for synthetic oxytocin formulations expired in the , enabling generic production, the drug's off-patent status facilitated widespread availability without monopolistic barriers, though remains a concern in global markets.

Societal Aspects

Regulatory Status

In the United States, oxytocin is classified as a prescription-only by the (FDA), requiring administration under medical supervision due to risks associated with its use in and postpartum hemorrhage control. Historically, prior to the FDA's discontinuation of letter categories in 2015, oxytocin was designated as C, indicating that showed adverse effects but there were no adequate human studies, though potential benefits may warrant use in pregnant individuals despite risks. Globally, oxytocin has been included on the World Health Organization's (WHO) Model List of since its inaugural publication in 1977, recognizing its critical role in preventing and treating postpartum hemorrhage in resource-limited settings. The (EMA) authorizes oxytocin injections for similar indications, including augmentation of labor and postpartum , with formulations meeting stringent quality standards for intravenous or intramuscular use. However, international variations exist; for instance, some Asian countries, including , have imposed restrictions on oxytocin's manufacture, import, and sale since 2018 to mitigate misuse risks, such as unauthorized applications in or unapproved cosmetic beauty enhancements. Oxytocin became off-patent in the mid-20th century, enabling widespread production of low-cost generic versions that enhance , particularly in developing regions. In 2024, the WHO prequalified additional oxytocin products from manufacturers like PT Sanbe Farma and others, ensuring quality-assured supplies for low-income settings to address postpartum hemorrhage effectively. Recent 2025 regulatory updates, including FDA draft guidance streamlining development by reducing analytical and clinical data requirements (as of October 2025), may facilitate approvals for recombinant oxytocin formulations, potentially lowering costs and improving global availability.

Counterfeits and Quality Issues

Counterfeit and substandard oxytocin products represent a critical to , particularly in low- and middle-income countries where supply chains are vulnerable to poor manufacturing, improper storage, and illicit trade. A of from 1990 to 2015 found that oxytocin failure rates in these settings ranged from 0% to 80%, with a median of 45.6% of samples failing to meet pharmacopeial standards for content and degradation products, and prevalence especially high in due to heat exposure and weak regulation. A 2020 WHO of uterotonic drugs, including oxytocin, in low- and middle-income countries found that nearly half (48.9%) of samples failed quality tests, often due to subpotency and thus ineffective against postpartum hemorrhage (PPH). These issues are exacerbated in low-resource settings, where over one-third of oxytocin samples may have inadequate content, leading to treatment failures during . Detection of counterfeit oxytocin relies on laboratory-based techniques such as (HPLC) with ultraviolet detection to quantify content and identify impurities or degradation. Field-level verification includes visual and physical inspection of packaging for hallmarks like holograms, batch numbers, and manufacturer details, often supported by portable devices for rapid screening of potency. To bolster authentic supply chains, initiatives like the Foundation's partnerships with WHO and promote procurement of prequalified oxytocin formulations, ensuring cold-chain integrity from manufacturer to facility and reducing the influx of substandard batches in systems. The health consequences of substandard oxytocin are severe, as ineffective doses fail to induce , resulting in uncontrolled PPH—the leading direct cause of maternal mortality worldwide, for about 27% of such deaths. In regions with high substandard , this contributes to thousands of preventable maternal deaths annually; for example, modeling in low-resource settings links poor-quality uterotonics to increased PPH incidence and associated complications like and organ failure. Economically, the impacts include substantial healthcare costs for emergency interventions and long-term productivity losses from maternal morbidity, with one analysis in estimating US$89 million in annual avertable expenses due to substandard uterotonics alone. Globally, the broader burden of substandard and falsified medicines, including oxytocin, is projected to exceed US$10 billion yearly in low- and middle-income countries. Efforts to address these issues have intensified through enforcement, including INTERPOL's Operation Pangea XVII in 2025, which coordinated actions across 90 countries and led to 769 arrests and the seizure of 50.4 million doses of illicit pharmaceuticals valued at $65 million, targeting production networks in high-risk areas like and . These operations focus on dismantling manufacturing sites and online distribution channels for essential medicines, including uterotonics, while enhancing regulatory frameworks to enforce quality standards in global trade.

Emerging and Non-Clinical Uses

Research Applications

Oxytocin has been investigated in clinical trials for its potential to alleviate core symptoms of autism spectrum disorder (ASD), particularly in enhancing and reducing repetitive behaviors. A 2023 meta-analysis of five randomized controlled trials involving 486 children with ASD found that intranasal oxytocin at doses of approximately 24 IU administered every other day for six weeks produced moderate improvements in narrow interests and repetitive behaviors, as measured by scales like the Repetitive Behavior Scale-Revised, with effects persisting at six-month follow-up in one study. Similarly, a 2025 dose-response indicated that higher intranasal doses (24-40 IU per day) yielded modest benefits for social impairments in ASD, though overall effects were small and required further validation through larger trials. In psychiatric applications, intranasal oxytocin shows promise for treating anxiety disorders, depression, and (PTSD) by modulating fear responses and social processing. A 2025 systematic review of 16 randomized controlled trials (n=834 participants) demonstrated that oxytocin enhanced functional connectivity between the and regions in individuals with (SAD) and PTSD, leading to reduced anxiety symptoms and improved fear extinction, with stronger effects in those with higher baseline anxiety levels. For depression, preliminary studies suggest oxytocin may augment effects by promoting prosocial behaviors, though evidence remains limited to small-scale trials. Ongoing phase II and III investigations, including those exploring intranasal formulations, continue to evaluate its in SAD as of 2025. As of 2025, these psychiatric applications remain investigational and are not approved for clinical use. Beyond and , oxytocin research extends to , cardiovascular protection, and via modulation. In , a 2025 study reported that topical or systemic oxytocin accelerated recovery of oral ulcers by promoting remodeling and reducing through its properties. For cardiovascular protection, oxytocin has been shown to mitigate risks in conditions like and by lowering and in cardiac tissue, as evidenced in preclinical models where it preserved heart function post-injury. In research, oxytocin influences differentiation and enhances regenerative potential; a 2024 review highlighted its role in promoting osteogenic and cardiomyogenic differentiation of mesenchymal stem cells, supporting applications in tissue repair for musculoskeletal and cardiac regeneration. As of 2025, these applications are investigational and not approved for clinical use. Research on oxytocin faces significant challenges, including inconsistent results attributed to genetic variations in the (OXTR) gene, which can alter receptor expression and responsiveness. Meta-analyses have linked OXTR polymorphisms, such as rs53576, to variable treatment outcomes in social behaviors and anxiety, with non-coding variants influencing and ASD traits, contributing to heterogeneous trial responses. Additionally, measurement inconsistencies in oxytocin levels—due to differences in assay methods like versus liquid chromatography-mass spectrometry—exacerbate replicability issues across studies. Ethical considerations are particularly acute in pediatric trials, where phase II investigations in children with ASD have raised concerns about long-term safety, from minors, and the balance between potential social benefits and risks of in vulnerable populations.

Veterinary and Other Uses

In , oxytocin is commonly administered to facilitate parturition in such as and by stimulating . Typical intramuscular doses range from 30 to 100 international units (IU) for cows and horses, depending on the animal's size and condition, with lower doses around 20-50 IU often used initially to avoid overstimulation. This application aids in managing dystocia and promoting timely delivery, mirroring its pharmacodynamic role in contraction across species. Oxytocin also plays a key role in inducing milk letdown in animals, enhancing ejection and thereby improving overall yield during . In heifers and cows, exogenous administration of as little as 0.10 IU can trigger effective milk ejection, with studies showing increased and yields in response to 20-40 IU doses, particularly in first-time milkers adapting to parlor systems. This practice supports agricultural productivity by reducing residual retention and optimizing harvest efficiency. Beyond direct obstetrical and lactational uses, oxytocin enhances reproduction in agricultural settings by improving transport and conception rates post-insemination. For instance, low-dose supplementation during in sows and ewes has been shown to boost rates by 10-20% through facilitated uterine . In , experimental applications involve oxytocin to induce spawning in species like African catfish (), where doses of 40 milli-international units per kg body weight, combined with other hormones, achieve voluntary spawning success rates up to 81.5%. Similar protocols have been tested in cyprinids such as Osteochilus vittatus, promoting and release for breeding programs. Non-clinical applications of oxytocin are limited but include its use in peptide research for developing veterinary therapeutics, leveraging synthetic formulations to study hormone analogs and receptor interactions. In the United States, oxytocin is FDA-approved for veterinary use in food-producing , with provisions under the Animal Medicinal Drug Use Clarification Act (AMDUCA) of 1994 allowing extralabel applications by licensed veterinarians to address specific therapeutic needs while ensuring .

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK507848/
  2. https://go.drugbank.com/drugs/DB00107
  3. https://medlineplus.gov/druginfo/meds/a682685.html
  4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018261s031lbl.pdf
  5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018248s049lbl.pdf
  6. https://www.ajog.org/article/S0002-9378%2823%2900439-8/fulltext
  7. https://www.acog.org/womens-health/faqs/labor-induction
  8. https://www.acog.org/news/news-releases/2017/09/acog-expands-recommendations-to-treat-postpartum-hemorrhage
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC6487388/
  10. https://www.mayoclinic.org/drugs-supplements/oxytocin-intravenous-route-intramuscular-route/description/drg-20065254
  11. https://list.essentialmeds.org/medicines/241
  12. https://www.acog.org/clinical/clinical-guidance/clinical-practice-guideline/articles/2024/01/first-and-second-stage-labor-management
  13. https://www.ahrq.gov/patient-safety/settings/labor-delivery/perinatal-care/modules/strategies/medication/tool-safe-oxytocin.html
  14. https://www.ncbi.nlm.nih.gov/books/NBK499988/
  15. https://reference.medscape.com/drug/pitocin-oxytocin-343132
  16. https://www.ncbi.nlm.nih.gov/books/NBK501490/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC7875314/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC8126197/
  19. https://www.drugs.com/pro/oxytocin.html
  20. https://www.ajog.org/article/S0002-9378(22)00840-7/fulltext
  21. https://www.drugs.com/monograph/oxytocin.html
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC7435109/
  23. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/tog.12809
  24. https://pubmed.ncbi.nlm.nih.gov/1153152/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC7526479/
  26. https://journals.physiology.org/doi/full/10.1152/physrev.2001.81.2.629
  27. https://pubmed.ncbi.nlm.nih.gov/10026815/
  28. https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2014.00068/full
  29. https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-022-05205-w
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC11438727/
  31. https://www.pdr.net/drug-summary/Pitocin-oxytocin-1666
  32. https://pubmed.ncbi.nlm.nih.gov/40121179/
  33. https://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.7b00991
  34. https://pubmed.ncbi.nlm.nih.gov/7354123/
  35. https://www.sciencedirect.com/science/article/pii/S0002937823002429
  36. https://journals.physiology.org/doi/10.1152/ajpendo.1998.274.5.E791
  37. https://pubmed.ncbi.nlm.nih.gov/2375427/
  38. https://pubmed.ncbi.nlm.nih.gov/9612235/
  39. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1361953/full
  40. https://pubchem.ncbi.nlm.nih.gov/compound/Oxytocin
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC2689356/
  42. https://www.researchgate.net/publication/367136676_Structures_of_the_arginine-vasopressin_and_oxytocin_receptor_signaling_complexes
  43. https://pubs.acs.org/doi/10.1021/ja01641a004
  44. https://pubmed.ncbi.nlm.nih.gov/17610261/
  45. https://pubmed.ncbi.nlm.nih.gov/14529494/
  46. https://www.drugs.com/pro/syntocinon.html
  47. http://www.uspbpep.com/usp29/v29240/usp29nf24s0_m60150.html
  48. https://www.usp-pqm.org/sites/default/files/pqms/article/stability-storage-oxytocin-jul2018.pdf
  49. https://pubs.acs.org/doi/10.1021/acs.biomac.6b00919
  50. https://physoc.onlinelibrary.wiley.com/doi/10.1113/jphysiol.1906.sp001148
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC3183515/
  52. https://hopp.uwpress.org/content/64/2/133
  53. https://www.nobelprize.org/prizes/chemistry/1955/vigneaud/facts/
  54. https://www.glowm.com/section-view/heading/Induction%20of%20Labor/item/130
  55. https://www.merckformothers.com/docs/Merck-for-Mothers-Evidence-for-Impact-2022.pdf
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC2689929/
  57. https://cen.acs.org/articles/83/i25/Oxytocin.html
  58. https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=1530592
  59. https://www.drugpatentwatch.com/p/generic/oxytocin
  60. https://extranet.who.int/prequal/sites/default/files/whopar_files/rh050part1v2.pdf
  61. https://www.fda.gov/media/189366/download
  62. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.13998
  63. https://www.who.int/news/item/10-07-2020-poor-quality-medicines-putting-lives-of-pregnant-women-at-risk
  64. https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-018-1671-y
  65. https://gh.bmj.com/content/3/4/e000725
  66. https://www.conceptfoundation.org/wp-content/uploads/2018/03/Oxytocin-Quality-Evidence-for-Action.pdf
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC11973754/
  68. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2696509
  69. https://pubmed.ncbi.nlm.nih.gov/37540265/
  70. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1477076/full
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC12514844/
  72. https://clinicaltrials.gov/study/NCT03566069
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC12028035/
  74. https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-016-0110-1
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC11592854/
  76. https://www.nature.com/articles/s41380-022-01719-z
  77. https://www.nejm.org/doi/full/10.1056/NEJMoa2103583
  78. https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=29aa28ea-36ef-431c-af1d-4aeec4c0e82a&type=pdf
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC9952595/
  80. https://www.journalofdairyscience.org/article/S0022-0302%2880%2983176-6/pdf
  81. https://www.sciencedirect.com/science/article/pii/S0022030224008750
  82. https://pubmed.ncbi.nlm.nih.gov/1894807/
  83. https://digitalcommons.unl.edu/coopext_swine/114/
  84. https://onlinelibrary.wiley.com/doi/abs/10.1111/rda.13931
  85. https://onlinelibrary.wiley.com/doi/abs/10.1111/are.14869
  86. https://www.bachem.com/knowledge-center/white-papers/peptides-in-veterinary-medicine/
  87. https://www.fda.gov/animal-veterinary/guidance-regulations/animal-medicinal-drug-use-clarification-act-1994-amduca
Add your contribution
Related Hubs
User Avatar
No comments yet.